{
    "name": "von Willebrand factor, recombinant",
    "comment": "Rx",
    "other_names": [
        "Vonvendi"
    ],
    "classes": [
        "Coagulation Factors"
    ],
    "source": "https://reference.medscape.com/drug/vonvendi-von-willebrand-factor-recombinant-1000061",
    "pregnancy": {
        "common": [
            "There are no studies of use in pregnant women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information regarding the presence of rVWF in human milk, the effects on the breastfed infant, or the effects on milk production",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for therapy and any potential adverse effects on the breastfed infant from the therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Life-threatening hypersensitivity reactions to rVWF or product constituents (ie, trisodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, hamster or mouse proteins)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Thromboembolic reactions (eg, DIC, venous thrombosis, PE, MI, stroke) can occur, particularly in patients with known risk factors for thrombosis; monitor for early signs and symptoms of thrombosis (eg, pain, swelling, discoloration, dyspnea, cough, hemoptysis, syncope)",
                "Hypersensitivity reactions, including anaphylaxis, may occur; immediately discontinue if severe allergic response occurs",
                "Neutralizing antibodies to vWF and/or FVIII may occur; if the expected plasma levels of vWF activity (vWF:RCo) are not attained, perform an appropriate assay to determine if anti-vWF or anti-FVIII inhibitors are present",
                "Monitor plasma levels of vWF:RCo and FVIII activity to avoid sustained excessive activity",
                "Monitor for development of vWF and/or FVIII inhibitors when suspected",
                "Advise patients to consult with healthcare provider prior to travel; while traveling, advise patients to bring adequate supply of the drug based on current regimen of treatment"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Infusion site paresthesia",
            "percent": null
        },
        {
            "name": "Chest discomfort",
            "percent": null
        },
        {
            "name": "Generalized pruritus",
            "percent": null
        },
        {
            "name": "Hot flush",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Increased heart rate",
            "percent": null
        },
        {
            "name": "ECG T",
            "percent": null
        },
        {
            "name": "wave inversion",
            "percent": null
        }
    ]
}